NEU 2.67% $14.56 neuren pharmaceuticals limited

Acadia, page-484

  1. 2,896 Posts.
    lightbulb Created with Sketch. 607
    Missing a sales target is one thing. NEU royalty receipts are all profit and largely still intact with an Acadia modest sales target miss.
    Acadia guidance for net sales in 2024 is still intact. A first sales milestone payment of US$50 million to Neuren is expected to be earned for 2024 on Daybue sales reaching US$250M.
    Things could be much worse.
    Kens
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.